Humacyte (NASDAQ:HUMA) Coverage Initiated at Barclays

Key Points

• Barclays has initiated coverage on Humacyte (NASDAQ:HUMA) with an "overweight" rating and a price target of $3.50, indicating a potential upside of 121.52% from its last closing price.
• Despite some analysts lowering their price targets, Humacyte currently has a consensus rating of "Buy" with an average price target of $9.75.
• Recent insider trading includes significant sales by CEO Laura E. Niklason and Director Brady W. Dougan, with over 4.4 million shares sold by insiders in the past ninety days.

Barclays began coverage on shares of Humacyte (NASDAQ:HUMA - Free Report) in a report published on Wednesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $3.50 price target on the stock.

Other analysts also recently issued reports about the stock. HC Wainwright lowered their price target on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Monday, August 11th. Benchmark lowered their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wall Street Zen cut Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday, August 17th. Finally, TD Cowen decreased their target price on Humacyte from $5.00 to $3.50 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $9.75.

Humacyte Stock Performance

Shares of HUMA traded down $0.05 during mid-day trading on Wednesday, reaching $1.51. The company had a trading volume of 1,735,669 shares, compared to its average volume of 4,003,729. The stock has a market capitalization of $238.35 million, a P/E ratio of -3.34 and a beta of 1.88. Humacyte has a 52-week low of $1.15 and a 52-week high of $6.77. The stock has a 50 day moving average of $2.13 and a two-hundred day moving average of $2.23. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. On average, analysts expect that Humacyte will post -1.27 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Laura E. Niklason sold 1,100,000 shares of Humacyte stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the transaction, the chief executive officer owned 591,685 shares in the company, valued at $964,446.55. The trade was a 65.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 1,100,000 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the transaction, the director directly owned 591,685 shares in the company, valued at approximately $964,446.55. The trade was a 65.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,482,090 shares of company stock worth $7,466,382. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. Columbia Advisory Partners LLC acquired a new stake in shares of Humacyte during the 1st quarter worth approximately $27,000. Lazari Capital Management Inc. acquired a new stake in Humacyte during the second quarter worth $27,000. Prudential Financial Inc. acquired a new stake in Humacyte during the second quarter worth $28,000. Financial Advisors Network Inc. purchased a new stake in Humacyte in the second quarter valued at $28,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at $30,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.